These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16711515)

  • 41. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modulation of prostate carcinoma cell growth and apoptosis by chromogranin A.
    Yu DS; Hsieh DS; Chang SY
    J Urol; 2003 Nov; 170(5):2031-5. PubMed ID: 14532847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chromogranin A in human disease.
    O'Connor DT; Mahata SK; Taupenot L; Mahata M; Livsey Taylor CV; Kailasam MT; Ziegler MG; Parmer RJ
    Adv Exp Med Biol; 2000; 482():377-88. PubMed ID: 11192598
    [No Abstract]   [Full Text] [Related]  

  • 44. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
    Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
    Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Divergent neuroendocrine differentiation in prostatic carcinoma.
    di Sant' Agnese PA
    Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer.
    Kalkner KM; Acosta S; Thorsson O; Frederiksen H; Nilsson A; Gustavsson B; Elingsbo M; Stridsberg M; Abrahamsson PA
    Prostate Cancer Prostatic Dis; 2006; 9(1):92-8. PubMed ID: 16231013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.
    Tarle M; Ahel MZ; Kovacić K
    Anticancer Res; 2002; 22(4):2525-9. PubMed ID: 12174956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of CI-958 in patients with hormone refractory prostate carcinoma.
    Philip Kuebler J; Moore T; Pritchard J; Kraut E
    Invest New Drugs; 2004 Apr; 22(2):181-4. PubMed ID: 14739667
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secretion of chromogranin A by peptide-producing endocrine neoplasms.
    O'Connor DT; Deftos LJ
    N Engl J Med; 1986 May; 314(18):1145-51. PubMed ID: 3007986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage.
    Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
    BMC Urol; 2004 Dec; 4(1):14. PubMed ID: 15588310
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Granin-A, parathyroid hormone-related protein, and calcitonin gene products in neuroendocrine prostate cancer.
    Deftos LJ
    Prostate Suppl; 1998; 8():23-31. PubMed ID: 9690660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
    Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
    Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
    Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prolactin and prostate cancer. II. Blood levels of prolactin in prostatic tumors].
    Maganto Pavón E; Mayayo Dehesa T; Mateos Torres JA; Verdú Tartajo F; de Blas Gómez V; Romero Aguirre C
    Arch Esp Urol; 1982; 35(3):171-8. PubMed ID: 6181745
    [No Abstract]   [Full Text] [Related]  

  • 55. Increased serum prolactin pituitary reserve in patients with prostatic neoplasms.
    Giuliani L; Pescatore D; Martorana G; Giberti C; Barreca T; Rolandi E
    Br J Urol; 1979 Oct; 51(5):390-2. PubMed ID: 93008
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Prolactin and cancer of the prostate (III). Changes in plasma prolactin and testosterone after hormone treatment in prostatic cancer].
    Maganto Pavón E; Mateos Torres JA; Mayayo Dehesa T; Allona Almagro A; Boronat Tormo F; Escudero Barrilero A
    Arch Esp Urol; 1982; 35(4):222-33. PubMed ID: 7138091
    [No Abstract]   [Full Text] [Related]  

  • 57. Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivo.
    Garde S; Sheth A; Porter AT; Pienta KJ
    Prostate; 1993; 22(3):225-33. PubMed ID: 8488155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
    Lilleby W; Paus E; Skovlund E; Fosså SD
    Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation.
    Sasagawa I; Nakada T; Kubota Y; Sawamura T; Izumiya K
    Int Urol Nephrol; 1995; 27(6):769-74. PubMed ID: 8725045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
    Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
    Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.